pLenti-puro-ARID1A Citations (10)

Originally described in: ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers.
Guan B, Wang TL, Shih IeM Cancer Res. 2011 Nov 1;71(21):6718-27. Epub 2011 Sep 7. PubMed Journal

---

Articles Citing pLenti-puro-ARID1A

Articles
The genomic landscape of nasopharyngeal carcinoma. Lin DC, Meng X, Hazawa M, Nagata Y, Varela AM, Xu L, Sato Y, Liu LZ, Ding LW, Sharma A, Goh BC, Lee SC, Petersson BF, Yu FG, Macary P, Oo MZ, Ha CS, Yang H, Ogawa S, Loh KS, Koeffler HP. Nat Genet. 2014 Aug;46(8):866-71. doi: 10.1038/ng.3006. Epub 2014 Jun 22. PubMed
The Chromatin Remodeling Component Arid1a Is a Suppressor of Spontaneous Mammary Tumors in Mice. Kartha N, Shen L, Maskin C, Wallace M, Schimenti JC. Genetics. 2016 Jun 8. pii: genetics.115.184879. PubMed
Mutational Landscape of Pediatric Acute Lymphoblastic Leukemia. Ding LW, Sun QY, Tan KT, Chien W, Mayakonda A, Yeoh AEJ, Kawamata N, Nagata Y, Xiao JF, Loh XY, Lin DC, Garg M, Jiang YY, Xu L, Lim SL, Liu LZ, Madan V, Sanada M, Fernandez LT, Hema Preethi SS, Lill M, Kantarjian HM, Kornblau SM, Miyano S, Liang DC, Ogawa S, Shih LY, Yang H, Koeffler HP. Cancer Res. 2017 Jan 15;77(2):390-400. doi: 10.1158/0008-5472.CAN-16-1303. Epub 2016 Nov 21. PubMed
GATA4 loss of function in liver cancer impedes precursor to hepatocyte transition. Enane FO, Shuen WH, Gu X, Quteba E, Przychodzen B, Makishima H, Bodo J, Ng J, Chee CL, Ba R, Seng Koh L, Lim J, Cheong R, Teo M, Hu Z, Ng KP, Maciejewski J, Radivoyevitch T, Chung A, Ooi LL, Tan YM, Cheow PC, Chow P, Chan CY, Lim KH, Yerian L, Hsi E, Toh HC, Saunthararajah Y. J Clin Invest. 2017 Sep 1;127(9):3527-3542. doi: 10.1172/JCI93488. Epub 2017 Jul 31. PubMed
ARID1A suppresses malignant transformation of human pancreatic cells via mediating senescence-associated miR-503/CDKN2A regulatory axis. Li ZY, Zhu SS, Chen XJ, Zhu J, Chen Q, Zhang YQ, Zhang CL, Guo TT, Zhang LM. Biochem Biophys Res Commun. 2017 Nov 18;493(2):1018-1025. doi: 10.1016/j.bbrc.2017.09.099. Epub 2017 Sep 20. PubMed
Identifying the ubiquitination targets of E6AP by orthogonal ubiquitin transfer. Wang Y, Liu X, Zhou L, Duong D, Bhuripanyo K, Zhao B, Zhou H, Liu R, Bi Y, Kiyokawa H, Yin J. Nat Commun. 2017 Dec 20;8(1):2232. doi: 10.1038/s41467-017-01974-7. PubMed
ARID1A ablation leads to multiple drug resistance in ovarian cancer via transcriptional activation of MRP2. Luo Q, Wu X, Zhang Y, Shu T, Ding F, Chen H, Zhao P, Chang W, Zhu X, Liu Z. Cancer Lett. 2018 Jul 28;427:9-17. doi: 10.1016/j.canlet.2018.04.013. Epub 2018 Apr 13. PubMed
Targeting AURKA-CDC25C axis to induce synthetic lethality in ARID1A-deficient colorectal cancer cells. Wu C, Lyu J, Yang EJ, Liu Y, Zhang B, Shim JS. Nat Commun. 2018 Aug 10;9(1):3212. doi: 10.1038/s41467-018-05694-4. PubMed
Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers. Ogiwara H, Takahashi K, Sasaki M, Kuroda T, Yoshida H, Watanabe R, Maruyama A, Makinoshima H, Chiwaki F, Sasaki H, Kato T, Okamoto A, Kohno T. Cancer Cell. 2019 Feb 11;35(2):177-190.e8. doi: 10.1016/j.ccell.2018.12.009. Epub 2019 Jan 24. PubMed
Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma. Kuroda T, Ogiwara H, Sasaki M, Takahashi K, Yoshida H, Kiyokawa T, Sudo K, Tamura K, Kato T, Okamoto A, Kohno T. Gynecol Oncol. 2019 Dec;155(3):489-498. doi: 10.1016/j.ygyno.2019.10.002. Epub 2019 Oct 8. PubMed

If you have published an article using this material, please email us at to have your article added to this page.